Andrew L. Frelinger

Publications

1. Protocol for assessing and visualizing cell microaggregate formation in whole blood by imaging flow cytometry. STAR Protoc. 2025 Jan 24; 6(1):103598. View Abstract
2. Flow Cytometry and Platelets. Clin Lab Med. 2024 Sep; 44(3):511-526. View Abstract
3. Dysregulation of platelet serotonin, 14-3-3, and GPIX in sudden infant death syndrome. Sci Rep. 2024 05 15; 14(1):11092. View Abstract
4. Platelet Physiology. Semin Thromb Hemost. 2024 Nov; 50(8):1173-1186. View Abstract
5. Outcomes of hematopoietic stem cell gene therapy for Wiskott-Aldrich syndrome. Blood. 2023 10 12; 142(15):1281-1296. View Abstract
6. OMIP-097: High-parameter phenotyping of human platelets by spectral flow cytometry. Cytometry A. 2023 12; 103(12):935-940. View Abstract
7. Clinical Cytometry for Platelets and Platelet Disorders. Clin Lab Med. 2023 09; 43(3):445-454. View Abstract
8. Platelet Phenotyping by Full Spectrum Flow Cytometry. Curr Protoc. 2023 Feb; 3(2):e687. View Abstract
9. Expert opinion on the use of platelet secretion assay for the diagnosis of inherited platelet function disorders: Communication from the ISTH SSC Subcommittee on Platelet Physiology. J Thromb Haemost. 2022 09; 20(9):2127-2135. View Abstract
10. Comprehensive phenotyping of human platelets by single-cell cytometry. Cytometry A. 2022 04; 101(4):290-297. View Abstract
11. Comparison and Analysis of Gut Microbiota in Children With IgA Vasculitis With Different Clinical Symptoms. Front Pediatr. 2021; 9:800677. View Abstract
12. Inhibition of transcription factor NFAT activity in activated platelets enhances their aggregation and exacerbates gram-negative bacterial septicemia. Immunity. 2022 02 08; 55(2):224-236.e5. View Abstract
13. Sex-specific platelet activation through protease-activated receptor-1 in patients undergoing cardiac catheterization. Atherosclerosis. 2021 12; 339:12-19. View Abstract
14. Platelet Activation and Reactivity in a Large Cohort of Patients with Gaucher Disease. Thromb Haemost. 2022 06; 122(6):951-960. View Abstract
15. Consensus recommendations on flow cytometry for the assessment of inherited and acquired disorders of platelet number and function: Communication from the ISTH SSC Subcommittee on Platelet Physiology. J Thromb Haemost. 2021 12; 19(12):3193-3202. View Abstract
16. Immunophenotypic Analysis of Platelets by Flow Cytometry. Curr Protoc. 2021 Jun; 1(6):e178. View Abstract
17. Platelet Immunophenotyping by High-Dimensional Mass Cytometry. Curr Protoc. 2021 May; 1(5):e112. View Abstract
18. Activation of platelet-rich plasma by pulse electric fields: Voltage, pulse width and calcium concentration can be used to control and tune the release of growth factors, serotonin and hemoglobin. PLoS One. 2021; 16(4):e0249209. View Abstract
19. Evaluation of Longitudinal Pain Study in Sickle Cell Disease (ELIPSIS) by patient-reported outcomes, actigraphy, and biomarkers. Blood. 2021 04 15; 137(15):2010-2020. View Abstract
20. Biomarkers of platelet activation and cardiovascular risk in the DAPT trial. J Thromb Thrombolysis. 2021 Apr; 51(3):675-681. View Abstract
21. Decreased platelet surface phosphatidylserine predicts increased bleeding in patients with severe factor VIII deficiency. J Thromb Haemost. 2021 04; 19(4):976-982. View Abstract
22. Platelet mass cytometry: Optimization of sample, reagent, and analysis parameters. Cytometry A. 2021 02; 99(2):170-179. View Abstract
23. Platelet surface GPIba, activated GPIIb-IIIa, and P-selectin levels in adult veno-arterial extracorporeal membrane oxygenation patients. Platelets. 2022 Jan 02; 33(1):116-122. View Abstract
24. Platelet count and disease - editorial policy. Platelets. 2020 Nov 16; 31(8):969-970. View Abstract
25. Platelet count and disease - editorial policy. Platelets. 2020 11 16; 31(8):969-970. View Abstract
26. An exploratory, randomised, placebo-controlled, 14 day trial of the soluble guanylate cyclase stimulator praliciguat in participants with type 2 diabetes and hypertension. Diabetologia. 2020 04; 63(4):733-743. View Abstract
27. Platelet surface marker analysis by mass cytometry. Platelets. 2020 Jul 03; 31(5):633-640. View Abstract
28. Using extracellular calcium concentration and electric pulse conditions to tune platelet-rich plasma growth factor release and clotting. Med Hypotheses. 2019 Apr; 125:100-105. View Abstract
29. PF-04447943, a Phosphodiesterase 9A Inhibitor, in Stable Sickle Cell Disease Patients: A Phase Ib Randomized, Placebo-Controlled Study. Clin Transl Sci. 2019 03; 12(2):180-188. View Abstract
30. Publisher Correction: GLS-409, an Antagonist of Both P2Y1 and P2Y12, Potently Inhibits Canine Coronary Artery Thrombosis and Reversibly Inhibits Human Platelet Activation. Sci Rep. 2018 Nov 29; 8(1):17580. View Abstract
31. Avatrombopag increases platelet count but not platelet activation in patients with thrombocytopenia resulting from liver disease. J Thromb Haemost. 2018 12; 16(12):2515-2519. View Abstract
32. Laboratory monitoring of P2Y12 inhibitors: communication from the SSC of the ISTH. J Thromb Haemost. 2018 11; 16(11):2341-2346. View Abstract
33. GLS-409, an Antagonist of Both P2Y1 and P2Y12, Potently Inhibits Canine Coronary Artery Thrombosis and Reversibly Inhibits Human Platelet Activation. Sci Rep. 2018 09 28; 8(1):14529. View Abstract
34. Tunable activation of therapeutic platelet-rich plasma by pulse electric field: Differential effects on clot formation, growth factor release, and platelet morphology. PLoS One. 2018; 13(9):e0203557. View Abstract
35. Mass Cytometry Reveals Distinct Platelet Subtypes in Healthy Subjects and Novel Alterations in Surface Glycoproteins in Glanzmann Thrombasthenia. Sci Rep. 2018 07 09; 8(1):10300. View Abstract
36. Novel aspects of antiplatelet therapy in cardiovascular disease. Res Pract Thromb Haemost. 2018 Jul; 2(3):439-449. View Abstract
37. Using flow cytometry to monitor glycoprotein IIb-IIIa activation. Platelets. 2018 Nov; 29(7):670-676. View Abstract
38. Incomplete reversibility of platelet inhibition following prolonged exposure to ticagrelor: reply. J Thromb Haemost. 2018 03; 16(3):607-608. View Abstract
39. Platelet Function in ITP, Independent of Platelet Count, Is Consistent Over Time and Is Associated with Both Current and Subsequent Bleeding Severity. Thromb Haemost. 2018 01; 118(1):143-151. View Abstract
40. Calpain-1 regulates platelet function in a humanized mouse model of sickle cell disease. Thromb Res. 2017 Dec; 160:58-65. View Abstract
41. High serum serotonin in sudden infant death syndrome. Proc Natl Acad Sci U S A. 2017 07 18; 114(29):7695-7700. View Abstract
42. Reply: Collapse of the Aspirin Empire: Is it Diabetic Gastroparesis or Cardioprotective Paresis? J Am Coll Cardiol. 2017 06 13; 69(23):2879. View Abstract
43. Incomplete reversibility of platelet inhibition following prolonged exposure to ticagrelor. J Thromb Haemost. 2017 05; 15(5):858-867. View Abstract
44. Enteric Coating and Aspirin Nonresponsiveness in Patients With Type 2 Diabetes Mellitus. J Am Coll Cardiol. 2017 Feb 14; 69(6):603-612. View Abstract
45. Whole Blood Analysis of Leukocyte-Platelet Aggregates. Curr Protoc Cytom. 2016 10 10; 78:6.15.1-6.15.10. View Abstract
46. Modification of Pulsed Electric Field Conditions Results in Distinct Activation Profiles of Platelet-Rich Plasma. PLoS One. 2016; 11(8):e0160933. View Abstract
47. Assessment of whole blood thrombosis in a microfluidic device lined by fixed human endothelium. Biomed Microdevices. 2016 08; 18(4):73. View Abstract
48. Diabetes mellitus, CYP2C19 genotype, and response to escalating doses of clopidogrel. Insights from the ELEVATE-TIMI 56 Trial. Thromb Haemost. 2016 07 04; 116(1):69-77. View Abstract
49. Platelet Physiology. Semin Thromb Hemost. 2016 Apr; 42(3):191-204. View Abstract
50. Synergistic Inhibition of Both P2Y1 and P2Y12 Adenosine Diphosphate Receptors As Novel Approach to Rapidly Attenuate Platelet-Mediated Thrombosis. Arterioscler Thromb Vasc Biol. 2016 Mar; 36(3):501-9. View Abstract
51. In Vivo and protease-activated receptor-1-mediated platelet activation in patients presenting for cardiac catheterization. Platelets. 2016 Jun; 27(4):308-16. View Abstract
52. New highly active antiplatelet agents with dual specificity for platelet P2Y1 and P2Y12 adenosine diphosphate receptors. Eur J Med Chem. 2016 Jan 01; 107:204-18. View Abstract
53. Aspirin response: Differences in serum thromboxane B2 levels between clinical studies. Platelets. 2016; 27(3):196-202. View Abstract
54. Soluble CD40 Ligand in Aspirin-Treated Patients Undergoing Cardiac Catheterization. PLoS One. 2015; 10(8):e0134599. View Abstract
55. Effects of eltrombopag on platelet count and platelet activation in Wiskott-Aldrich syndrome/X-linked thrombocytopenia. Blood. 2015 Sep 10; 126(11):1367-78. View Abstract
56. Platelet function tests, independent of platelet count, are associated with bleeding severity in ITP. Blood. 2015 Aug 13; 126(7):873-9. View Abstract
57. Platelet-rich plasma stimulated by pulse electric fields: Platelet activation, procoagulant markers, growth factor release and cell proliferation. Platelets. 2016; 27(2):128-35. View Abstract
58. A review of platelet secretion assays for the diagnosis of inherited platelet secretion disorders. Thromb Haemost. 2015 Jul; 114(1):14-25. View Abstract
59. Platelet activation using electric pulse stimulation: growth factor profile and clinical implications. J Trauma Acute Care Surg. 2014 Sep; 77(3 Suppl 2):S94-S100. View Abstract
60. The effect of prasugrel on ADP-stimulated markers of platelet activation in patients with sickle cell disease. Platelets. 2015; 26(5):474-9. View Abstract
61. Variability of individual platelet reactivity over time in patients treated with clopidogrel: insights from the ELEVATE-TIMI 56 trial. J Am Coll Cardiol. 2014 Jul 29; 64(4):361-8. View Abstract
62. Do immature platelet levels in chest pain patients presenting to the emergency department aid in the diagnosis of acute coronary syndrome? Int J Lab Hematol. 2015 Feb; 37(1):112-9. View Abstract
63. Antiplatelet activity, P2Y1 and P2Y12 inhibition, and metabolism in plasma of stereoisomers of diadenosine 5',5'?-P¹ ,P4-dithio-P²,P³-chloromethylenetetraphosphate. PLoS One. 2014; 9(4):e94780. View Abstract
64. A phase 1 study of prasugrel in patients with sickle cell disease: effects on biomarkers of platelet activation and coagulation. Thromb Res. 2014 Feb; 133(2):190-5. View Abstract
65. Clinical and laboratory significance of defective P2Y(12) pathway function in patients with myeloproliferative neoplasms: a pilot study. Acta Haematol. 2013; 130(3):181-7. View Abstract
66. A phase 1 study of prasugrel in patients with sickle cell disease: pharmacokinetics and effects on ex vivo platelet reactivity. Br J Clin Pharmacol. 2013 Jun; 75(6):1433-44. View Abstract
67. The aryl hydrocarbon receptor directs hematopoietic progenitor cell expansion and differentiation. Blood. 2013 Jul 18; 122(3):376-85. View Abstract
68. P2Y12 receptor blockade augments glycoprotein IIb-IIIa antagonist inhibition of platelet activation, aggregation, and procoagulant activity. J Am Heart Assoc. 2013 May 15; 2(3):e000026. View Abstract
69. Differences in platelet function in patients with acute myeloid leukemia and myelodysplasia compared to equally thrombocytopenic patients with immune thrombocytopenia: a reply to a rebuttal. J Thromb Haemost. 2013 May; 11(5):1002-3. View Abstract
70. Platelet activation and inhibition in sickle cell disease (pains) study. Platelets. 2014; 25(1):27-35. View Abstract
71. A double-blind, randomized, multicenter phase 2 study of prasugrel versus placebo in adult patients with sickle cell disease. J Hematol Oncol. 2013 Feb 17; 6:17. View Abstract
72. Clopidogrel pharmacokinetics and pharmacodynamics vary widely despite exclusion or control of polymorphisms (CYP2C19, ABCB1, PON1), noncompliance, diet, smoking, co-medications (including proton pump inhibitors), and pre-existent variability in platelet function. J Am Coll Cardiol. 2013 Feb 26; 61(8):872-9. View Abstract
73. Decrease in high on-treatment platelet reactivity (HPR) prevalence on switching from clopidogrel to prasugrel: insights from the switching anti-platelet (SWAP) study. Thromb Haemost. 2013 Feb; 109(2):347-55. View Abstract
74. Modified diadenosine tetraphosphates with dual specificity for P2Y1 and P2Y12 are potent antagonists of ADP-induced platelet activation. J Thromb Haemost. 2012 Dec; 10(12):2573-80. View Abstract
75. A randomized, 2-period, crossover design study to assess the effects of dexlansoprazole, lansoprazole, esomeprazole, and omeprazole on the steady-state pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers. J Am Coll Cardiol. 2012 Apr 03; 59(14):1304-11. View Abstract
76. In vivo effects of eltrombopag on platelet function in immune thrombocytopenia: no evidence of platelet activation. Blood. 2012 Apr 26; 119(17):4066-72. View Abstract
77. Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease. JAMA. 2011 Nov 23; 306(20):2221-8. View Abstract
78. Differences in platelet function in patients with acute myeloid leukemia and myelodysplasia compared to equally thrombocytopenic patients with immune thrombocytopenia. J Thromb Haemost. 2011 Nov; 9(11):2302-10. View Abstract
79. The human endogenous circadian system causes greatest platelet activation during the biological morning independent of behaviors. PLoS One. 2011; 6(9):e24549. View Abstract
80. Intrinsic platelet reactivity before P2Y12 blockade contributes to residual platelet reactivity despite high-level P2Y12 blockade by prasugrel or high-dose clopidogrel. Results from PRINCIPLE-TIMI 44. Thromb Haemost. 2011 Aug; 106(2):219-26. View Abstract
81. Effects of in vitro adult platelet transfusions on neonatal hemostasis. J Thromb Haemost. 2011 May; 9(5):1020-8. View Abstract
82. The influence of intermittent hypoxemia on platelet activation in obese patients with obstructive sleep apnea. J Clin Sleep Med. 2011 Apr 15; 7(2):172-8. View Abstract
83. A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 Trial. Eur Heart J. 2011 Apr; 32(7):838-46. View Abstract
84. Increased platelet inhibition after switching from maintenance clopidogrel to prasugrel in patients with acute coronary syndromes: results of the SWAP (SWitching Anti Platelet) study. J Am Coll Cardiol. 2010 Sep 21; 56(13):1017-23. View Abstract
85. The Platelet Activity After Clopidogrel Termination (PACT) study. Circ Cardiovasc Interv. 2010 Oct; 3(5):442-9. View Abstract
86. Platelet reactivity with prolonged aspirin treatment--steady going at 2 year. Circ J. 2010 Jun; 74(6):1077-8. View Abstract
87. Soluble CD40 ligand is elevated in type 1 diabetic nephropathy but not predictive of mortality, cardiovascular events or kidney function. Platelets. 2010; 21(7):525-32. View Abstract
88. Association of cyclooxygenase-1-dependent and -independent platelet function assays with adverse clinical outcomes in aspirin-treated patients presenting for cardiac catheterization. Circulation. 2009 Dec 22; 120(25):2586-96. View Abstract
89. Agonist and antagonist effects of diadenosine tetraphosphate, a platelet dense granule constituent, on platelet P2Y1, P2Y12 and P2X1 receptors. Thromb Res. 2010 Feb; 125(2):159-65. View Abstract
90. Targeted inhibition of the serotonin 5HT2A receptor improves coronary patency in an in vivo model of recurrent thrombosis. J Thromb Haemost. 2010 Feb; 8(2):331-40. View Abstract
91. Nephropathy in type 1 diabetes is associated with increased circulating activated platelets and platelet hyperreactivity. Platelets. 2009 Nov; 20(7):513-9. View Abstract
92. Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial. Eur Heart J. 2009 Jul; 30(14):1753-63. View Abstract
93. The platelet hyporeactivity of extremely low birth weight neonates is age-dependent. Thromb Res. 2009 May; 124(1):42-5. View Abstract
94. Aspirin 'resistance': role of pre-existent platelet reactivity and correlation between tests. J Thromb Haemost. 2008 Dec; 6(12):2035-44. View Abstract
95. Effects of physiologic agonists on canine whole blood flow cytometry assays of leukocyte-platelet aggregation and platelet activation. Vet Immunol Immunopathol. 2008 Jun 15; 123(3-4):345-52. View Abstract
96. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial. Circulation. 2007 Dec 18; 116(25):2923-32. View Abstract
97. The active metabolite of prasugrel inhibits adenosine diphosphate- and collagen-stimulated platelet procoagulant activities. J Thromb Haemost. 2008 02; 6(2):359-65. View Abstract
98. Effect of adenosine A2 receptor stimulation on platelet activation-aggregation: differences between canine and human models. Thromb Res. 2008; 121(5):689-98. View Abstract
99. The active metabolite of prasugrel inhibits ADP-stimulated thrombo-inflammatory markers of platelet activation: Influence of other blood cells, calcium, and aspirin. Thromb Haemost. 2007 Jul; 98(1):192-200. View Abstract
100. Cystic fibrosis heterozygotes do not have increased platelet activation. Thromb Res. 2007; 121(2):159-62. View Abstract
101. Indices of platelet activation and the stability of coronary artery disease. J Thromb Haemost. 2007 Apr; 5(4):761-5. View Abstract
102. Measuring antiplatelet drug effects in the laboratory. Thromb Res. 2007; 120(3):323-36. View Abstract
103. Current options in platelet function testing. Am J Cardiol. 2006 Nov 20; 98(10A):4N-10N. View Abstract
104. Evidence that pre-existent variability in platelet response to ADP accounts for 'clopidogrel resistance'. J Thromb Haemost. 2007 Jan; 5(1):75-81. View Abstract
105. Preconditioning ischemia attenuates molecular indices of platelet activation-aggregation. J Thromb Haemost. 2006 Dec; 4(12):2670-7. View Abstract
106. Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1- and cyclooxygenase-2-independent pathway: a 700-patient study of aspirin resistance. Circulation. 2006 Jun 27; 113(25):2888-96. View Abstract
107. Effects of platelet binding on whole blood flow cytometry assays of monocyte and neutrophil procoagulant activity. J Thromb Haemost. 2005 Nov; 3(11):2563-70. View Abstract
108. Clopidogrel linking evaluation of platelet response variability to mechanism of action. J Am Coll Cardiol. 2005 Aug 16; 46(4):646-7. View Abstract
109. Platelet activation in cystic fibrosis. Blood. 2005 Jun 15; 105(12):4635-41. View Abstract
110. GPIIb-IIIa antagonists reduce thromboinflammatory processes in patients with acute coronary syndromes undergoing percutaneous coronary intervention. J Thromb Haemost. 2005 Feb; 3(2):312-20. View Abstract
111. Application of flow cytometry to platelet disorders. Semin Thromb Hemost. 2004 Oct; 30(5):501-11. View Abstract
112. GPIIb/IIIa inhibitor-induced dethrombosis. J Thromb Thrombolysis. 2004 Aug; 18(1):11-7. View Abstract
113. Release of soluble CD40L from platelets is regulated by glycoprotein IIb/IIIa and actin polymerization. J Am Coll Cardiol. 2004 Jun 16; 43(12):2319-25. View Abstract
114. Combined effects of mild hypothermia and glycoprotein IIb/IIIa antagonists on platelet-platelet and leukocyte-platelet aggregation. Am J Cardiol. 2003 Nov 01; 92(9):1099-101. View Abstract
115. Whole blood analysis of leukocyte-platelet aggregates. Curr Protoc Cytom. 2003 May; Chapter 6:Unit 6.15. View Abstract
116. The cleaved peptide of PAR1 is a more potent stimulant of platelet-endothelial cell adhesion than is thrombin. J Vasc Surg. 2003 Feb; 37(2):440-5. View Abstract
117. Quantification of abciximab-induced platelet inhibition is assay dependent: a comparative study in patients undergoing percutaneous coronary intervention. Am Heart J. 2003 Feb; 145(2):e6. View Abstract
118. An additional mechanism of action of abciximab: dispersal of newly formed platelet aggregates. Thromb Haemost. 2002 Jun; 87(6):1020-5. View Abstract
119. Immunophenotypic analysis of platelets. Curr Protoc Cytom. 2002 Feb; Chapter 6:Unit 6.10. View Abstract
120. Leukocyte-platelet aggregation, platelet surface P-selectin, and platelet surface glycoprotein IIIa after percutaneous coronary intervention: Effects of dalteparin or unfractionated heparin in combination with abciximab. Am Heart J. 2001 Nov; 142(5):790-8. View Abstract
121. Circulating monocyte-platelet aggregates are an early marker of acute myocardial infarction. J Am Coll Cardiol. 2001 Oct; 38(4):1002-6. View Abstract
122. Dissociation of glycoprotein IIb/IIIa antagonists from platelets does not result in fibrinogen binding or platelet aggregation. Circulation. 2001 Sep 18; 104(12):1374-9. View Abstract
123. Laser scanning cytometry: a novel method for the detection of platelet--endothelial cell adhesion. Cytometry. 2001 Apr 01; 43(4):308-13. View Abstract
124. GPIIb-IIIa antagonist-induced reduction in platelet surface factor V/Va binding and phosphatidylserine expression in whole blood. Thromb Haemost. 2000 Sep; 84(3):492-8. View Abstract
125. Evaluation of platelet function by flow cytometry. Methods. 2000 Jul; 21(3):259-70. View Abstract
126. Progress in point-of-care laboratory testing for assessing platelet function. Am Heart J. 1998 Oct; 136(4 Pt 2 Su):S51-65. View Abstract
127. Novel methods for assessing platelet function. Am Heart J. 1998 May; 135(5 Pt 2 Su):S184-6. View Abstract
128. Prevention of experimental carotid artery thrombosis by applaggin. J Pharmacol Exp Ther. 1993 Nov; 267(2):809-14. View Abstract
129. Arg-Gly-Asp-dependent occupancy of GPIIb/IIIa by applaggin: evidence for internalization and cycling of a platelet integrin. Blood. 1993 Jan 01; 81(1):62-9. View Abstract
130. A spontaneous mutation of integrin alpha IIb beta 3 (platelet glycoprotein IIb-IIIa) helps define a ligand binding site. J Biol Chem. 1992 Feb 25; 267(6):3789-94. View Abstract
131. Localization of a PlA1 epitope to the amino terminal 66 residues of platelet glycoprotein IIIa. Blood. 1992 Feb 01; 79(3):559-62. View Abstract
132. Monoclonal antibodies to ligand-occupied conformers of integrin alpha IIb beta 3 (glycoprotein IIb-IIIa) alter receptor affinity, specificity, and function. J Biol Chem. 1991 Sep 15; 266(26):17106-11. View Abstract
133. Activation of the fibrinogen receptor on human platelets exposed to alpha chymotrypsin. Relationship with a major proteolytic cleavage at the carboxyterminus of the membrane glycoprotein IIb heavy chain. Eur J Biochem. 1991 Sep 01; 200(2):437-47. View Abstract
134. Ligands "activate" integrin alpha IIb beta 3 (platelet GPIIb-IIIa). Cell. 1991 May 03; 65(3):409-16. View Abstract
135. Analysis of platelet aggregation disorders based on flow cytometric analysis of membrane glycoprotein IIb-IIIa with conformation-specific monoclonal antibodies. Blood. 1990 Nov 15; 76(10):2017-23. View Abstract
136. A beta 3 integrin mutation abolishes ligand binding and alters divalent cation-dependent conformation. Science. 1990 Aug 24; 249(4971):915-8. View Abstract
137. Selective inhibition of integrin function by antibodies specific for ligand-occupied receptor conformers. J Biol Chem. 1990 Apr 15; 265(11):6346-52. View Abstract
138. Isolation and characterization of a platelet membrane protein related to the vitronectin receptor. J Biol Chem. 1989 Mar 05; 264(7):3742-9. View Abstract
139. Occupancy of an adhesive glycoprotein receptor modulates expression of an antigenic site involved in cell adhesion. J Biol Chem. 1988 Sep 05; 263(25):12397-402. View Abstract
140. Molecular cloning and chemical synthesis of a region of platelet glycoprotein IIb involved in adhesive function. Proc Natl Acad Sci U S A. 1987 Oct; 84(20):7114-8. View Abstract
141. Topography of N-CAM structural and functional determinants. I. Classification of monoclonal antibody epitopes. J Cell Biol. 1986 Nov; 103(5):1721-7. View Abstract
142. Topography of N-CAM structural and functional determinants. II. Placement of monoclonal antibody epitopes. J Cell Biol. 1986 Nov; 103(5):1729-37. View Abstract
143. The role of the methionine residues in the structure and function of parathyroid hormone. Arch Biochem Biophys. 1986 Feb 01; 244(2):641-9. View Abstract
144. Oxidized forms of parathyroid hormone with biological activity. Separation and characterization of hormone forms oxidized at methionine 8 and methionine 18. J Biol Chem. 1984 May 10; 259(9):5507-13. View Abstract
145. Specific cleavage of bovine parathyroid hormone catalyzed by an endopeptidase from bovine kidney. J Biol Chem. 1981 Nov 25; 256(22):11483-8. View Abstract
146. Plasma immunoreactive calcitonin in lung cancer. J Clin Endocrinol Metab. 1980 Apr; 50(4):659-66. View Abstract
147. Tumor growth and calcitonin during serial transplantation of rat medullary thyroid carcinoma. Endocrinology. 1979 Jul; 105(1):27-32. View Abstract
148. Plasma immunoreactive calcitonin in lung cancer. Endocr Res Commun. 1979; 6(2):169-90. View Abstract
149. Acute and chronic fluctuations of immunoreactive and biologically active plasma calcitonin in the rat. Endocrinology. 1978 Dec; 103(6):2180-6. View Abstract
Show All Publications Show Fewer Publications